Vero Bioscience provides CLIA‑compatible mass‑spectrometry assays that quantify organ‑specific protein panels in plasma and convert them into age‑adjusted functional scores using its Organ Compass™ platform. The solution includes a secure cloud analytics portal with batch processing, trend visualization, and API access, enabling pharmaceutical R&D teams, CROs, and preventive‑medicine clinics to obtain quantitative organ‑health biomarkers for trial endpoints and personalized monitoring.
Funding
$30M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
PHFounders
Product
Problem
Current clinical practice lacks quantitative, organ‑specific biomarkers that can reliably track the biological aging process and predict functional decline. Without such metrics, clinicians and researchers cannot assess organ health trajectories or evaluate interventions with sufficient precision.
Solution
Vero Bioscience leverages high‑resolution proteomics to discover and validate panels of circulating protein markers that reflect the physiological state of individual organs. The proprietary Organ Compass™ platform translates these markers into a calibrated scoring system that quantifies organ function relative to age‑adjusted baselines. By integrating mass‑spectrometry data with machine‑learning models, the company delivers reproducible assays that can be deployed in clinical laboratories or research biobanks. The resulting reports enable longitudinal monitoring, risk stratification, and data‑driven decision making for therapeutic development or personalized health management.
Target Audience
Primary customers are pharmaceutical R&D teams, clinical research organizations, and longevity or preventive‑medicine clinics seeking quantitative organ‑health endpoints for trials, drug development, or personalized monitoring.
Features
- Targeted mass‑spectrometry workflow optimized for low‑volume plasma samples, delivering sub‑nanogram sensitivity across >1,000 protein targets
- AI‑augmented biomarker discovery pipeline that correlates proteomic signatures with organ‑specific functional outcomes in large cohort datasets
- Organ Compass™ scoring algorithm, calibrated against age‑matched reference populations and validated in multi‑site clinical studies
- CLIA‑compatible assay kits with standardized reagents, SOPs, and quality‑control metrics for seamless laboratory integration
- Secure cloud‑based analytics portal offering batch processing, trend visualization, and API access for EHR or research data pipelines
- Regulatory‑ready documentation package supporting IND and biomarker qualification submissions